Page 53 - Medication Guide News Today

ABBVie today announced the presentation of new data on RINVOQ ® SKYRIZI ® and HUMIRA ® across multiple rheumatic diseases at the American College of Rheumatology's annual meeting to be held virtually Nov. 3-9 . A total of 38 abstracts, including two oral presentations and one plenary session presentation, will be presented from a broad range of studies in rheumatoid arthritis, psoriatic arthritis and ankylosing ...

KEYTRUDA Continued To Improve Recurrence-Free Survival Compared to Placebo as Adjuvant Therapy for Patients With Resected Stage IIB or IIC Melanoma at 2 nd Interim Analysis of Phase 3 KEYNOTE-716 Trial Exploratory 7-Year Follow-Up Data for KEYTRUDA in Advanced Melanoma Showed 38% of Patients Treated With KEYTRUDA Were Alive at 7 Years Merck known as MSD outside the United States and Canada, today announced new data ...

Investegate announcements from Indivior PLC, 3rd Quarter Results

Data to highlight the safety, tolerability and efficacy of LUPKYNIS in patients with lupus nephritis Aurinia Pharmaceuticals Inc. a biopharma company committed to delivering therapeutics that change the course of autoimmune disease, today announced that data from multiple studies of LUPKYNIS™ for the treatment of people with lupus nephritis a serious complication of systemic lupus erythematosus resulting in ...

In Out's "Spilling the Tea on Me" series, the star opens up about finding her voice.

KEYTRUDA Is Now Approved in Combination With Chemotherapy as First-Line Treatment for Patients With Locally Recurrent Unresectable or Metastatic TNBC Whose Tumors Express PD-L1 and Who Have Not Received Prior Chemotherapy for Metastatic Disease KEYTRUDA Is the First Anti-PD-1 Therapy in Combination With Chemotherapy to Demonstrate Statistically Significant Overall Survival in These Patients; Based on Results From ...

/PRNewswire/ -- The U.S. Food and Drug Administration approved the first interchangeable biosimilar product to treat certain inflammatory diseases. Cyltezo...

Positive Opinion Granted for Advanced Renal Cell Carcinoma Based on Significant Progression-Free Survival (PFS), Overall Survival (OS) and Objective Response Rate (ORR) Benefit Compared to Sunitinib

Positive Opinion Granted for Advanced Renal Cell Carcinoma Based on Significant Progression-Free Survival Overall Survival and Objective Response Rate Benefit Compared to Sunitinib in CLEARKEYNOTE-581 Trial Positive Opinion Granted for Advanced Endometrial Carcinoma Based on Significant OS and PFS Benefit Compared to Chemotherapy in KEYNOTE-775Study 309 Trial Merck known as MSD outside the United States and Canada, ...

Treatment with Zeposia demonstrated a low annualized relapse rate of 0.103 and more than 70% of patients were relapse-free at four years Safety was consistent with prior findings and the established safety profile of Zeposia in up to 5 years of follow-up Bristol Myers Squibb today announced interim results from the Phase 3 open-label extension trial DAYBREAK, demonstrating the long-term efficacy and safety profile ...